ABCB5外显子测序发现黑色素瘤复发突变并增强增殖与侵袭能力
本研究对640例黑色素瘤样本进行ABCB5外显子测序,发现13.75%存在ABCB5突变,突变集中于药物结合口袋与核苷酸结合域;代表性突变降低ABCB5基础ATP水解活性;表达突变型ABCB5的黑色素瘤细胞增殖与迁移能力增强,提示ABCB5可能作为抑癌基因参与黑色素瘤发生发展。
要点
- 640例黑色素瘤样本中ABCB5突变率为13.75%,突变位于药物结合口袋和核苷酸结合域。
- 代表性ABCB5突变降低基础ATP水解活性,突变型表达细胞增殖与迁移能力增强。
- ABCB5突变样本中NRAS突变占75%、CDKN2A突变占62.5%,BRAF V600E占25%。
核心结论
- ABCB5在黑色素瘤中频繁突变,代表性突变降低ATP水解活性并增强细胞增殖与迁移,提示其可能作为抑癌基因参与黑色素瘤发展。
研究设计与样本
- 对640例黑色素瘤样本进行ABCB5外显子测序分析突变谱。
- 选取4个代表性ABCB5突变进行ATPase活性检测。
- 在4株不同遗传背景的黑色素瘤细胞系中研究突变型ABCB5表达对增殖和迁移的影响。
主要发现
- 640例黑色素瘤样本中13.75%存在ABCB5突变。
- ABCB5蛋白存在两个突变热点,分别位于药物结合口袋和核苷酸结合域。
- 代表性突变导致ABCB5基础ATP水解减少。
- ABCB5突变样本中NRAS突变占75%、CDKN2A突变占62.5%,BRAF V600E突变占25%,PTEN未见突变。
- 表达突变型ABCB5的黑色素瘤细胞增殖和迁移能力增加。
关键数值与推荐
- ABCB5突变率13.75%(640例黑色素瘤样本)。
- ABCB5突变样本中NRAS突变75%、CDKN2A突变62.5%、BRAF V600E突变25%。
临床怎么用
- 提示ABCB5突变状态可能作为黑色素瘤分子特征之一,但尚需进一步验证其临床分层价值。
局限性
- 摘要未报告突变功能实验的具体样本量、统计方法与P值,结论外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ABCB5 is an ABC transporter that was shown to confer low-level multidrug resistance in cancer. In this study, we show that ABCB5 was mutated in 13.75% of the 640 melanoma samples analyzed. Besides nonsense mutations, two mutation hotspots were found in the ABCB5 protein, in the drug-binding pocket and the nucleotide-binding domains. Four mutations, which are representative of the mutation pattern, were selected. ATPase assays showed that these mutations resulted in a decrease in basal ATP hydrolysis by ABCB5. To select informative melanoma cell lines, mutational profiles of the clinical samples were further analyzed. This study showed mutations in the tumor suppressor CDKN2A gene and the NRAS oncogene in 62.5% and 75%, respectively of the samples that had mutations in the ABCB5 gene. No mutation was found in the tumor suppressor PTEN gene, whereas the activating V600E mutation in the BRAF oncogene was found in 25% of the samples with a mutated ABCB5 gene. Studies in four melanoma cell lines with various genetic backgrounds showed an increase in the proliferation and migration capacity of mutant ABCB5-expressing cells, suggesting that ABCB5 plays a role in the development of melanoma as a tumor suppressor gene.
引用
- Sana G, Madigan JP, Gartner JJ, et al. Exome Sequencing of ABCB5 Identifies Recurrent Melanoma Mutations that Result in Increased Proliferative and Invasive Capacities. J Invest Dermatol. 2019. PMID: 30905807. doi:10.1016/j.jid.2019.01.036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。